NOTE 5 INVESTMENTS

12 Months Ended

Mar. 31, 2020

Notes

NOTE 5 INVESTMENTS

NOTE 5 INVESTMENTS

The following table summarizes the Company’s investment portfolio at March 31, 2020 and 2019.

		As of March 31
		2020			2019
Number of portfolio companies		28			18
Fair value	$	2,665,499		$	1,498,048
Cost	$	2,726,545		$	1,498,048
% of portfolio at cost
Convertible notes		1,578,002	58%	$	814,048	54%
Preferred stock		651,497	24%		351,500	23%
Common stock		73,500	3%		-	0%
SAFE		126,500	5%		126,500	8%
Other ownership units		236,000	9%		206,000	14%
Total	$	2,665,499	98%	$	1,498,048	100%

Our investment portfolio represents approximately 99.9% of our net assets at March 31, 2020 and 95.8% at March 31, 2019. Investments in early stage start up private operating entities, are valued based on available metrics, such as relevant market multiples and comparable company valuations, company specific-financial data including actual and projected results and independent third party valuation estimates. These investments are designated as Level 3 assets.

We focus on making our investments are made in the United States, Canada and Israel.

As of March 31, 2019
	America	Canada	Israel	Total
Fair value beginning of year	$ 1,448,048	$ 50,000	$            -	$ 1,498,048
New investments	783,497	195,000	250,000	1,228,497
Proceeds from sale of investments	-	-	-	-
Realized gains	-	-	-	-
Write down of investment	(61,046)	-	-	(61,046)
Fair value March 31, 2020	$ 2,170,499	$ 245,000	$ 250,000	$ 2,665,499
As of March 31, 2018
	America	Canada	Israel	Total
Fair value beginning of year	$               -	$           -	$            -	$               -
New investments	1,448,048	50,000	-	1,498,048
Proceeds from sale of investments	-	-	-	-
Realized gains	-	-	-	-
Write down of investment	-	-	-	-
Fair value March 31, 2019	$ 1,448,048	$ 50,000	$            -	$ 1,498,048

Working on the experience of our technical advisors, we limit our investments to fintech, technology, and life sciences.

As of March 31, 2019
	Fintech	Technology	Life science	Total
Fair value beginning of year	$ 101,500	$ 262,548	$ 1,134,000	$ 1,498,048
New investments	-	483,500	744,997	1,228,497
Proceeds from sale of investments	-	-	-	-
Realized gains	-	-	-	-
Write down of investment	-	(61,046)	-	(61,046)
Fair value March 31, 2020	$ 101,500	$ 685,002	$ 1,878,997	$ 2,665,499
As of March 31, 2018
	Fintech	Technology	Life science	Total
Fair value beginning of year	$            -	$            -	$               -	$               -
New investments	101,500	262,548	1,134,000	1,498,048
Proceeds from sale of investments	-	-	-	-
Realized gains	-	-	-	-
Write down of investment	-	-	-	-
Fair value March 31, 2019	$ 101,500	$ 262,548	$ 1,134,000	$ 1,498,048

We invest in early stage private companies developing products or solutions in the fields of fintech, technology and life sciences. Typically we are investing in interest bearing notes that may be convertible into equity securities upon the completion of qualified subsequent financings, preferred stock, SAFEs or other forms of ownership.

	Convertible notes	Preferred stock	Common stock	SAFEs	Other ownership interests	Total
As of March 31, 2019
Fair value beginning of year	$ 764,048	$ 401,500	$ 126,500	$            -	$ 206,000	$ 1,498,048
New investments	825,000	299,997	-	73,500	30,000	1,228,497
Proceeds from sale of investments	-	-	-	-	-	-
Realized gains	-	-	-	-	-	-
Write down of investment	(61,046)	-	-	-	-	(61,046)
Fair value March 31, 2020	$ 1,528,002	$ 701,497	$ 126,500	$ 73,500	$ 236,000	$ 2,665,499
	Convertible notes	Preferred stock	Common stock	SAFEs	Other ownership interests	Total
As of March 31, 2018	$            --	$            -	$            -	$            -	$            -	$               -
Fair value beginning of year	-	-	-	-	-	-
New investments	764,048	401,500	126,500	-	206,000	1,498,048
Proceeds from sale of investments	-	-	-	-	-	-
Realized gains	-	-	-	-	-	-
Write down of investment	-	-	-	-	-	-
Fair value March 31, 2019	$ 764,048	$ 401,500	$ 126,500	$            -	$ 206,000	$ 1,498,048